- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04699721
Klinisk undersøgelse af neoadjuverende kemoterapi og immunterapi kombineret med probiotika hos patienter med potentiel/resektabel NSCLC
Klinisk undersøgelse af neoadjuverende kemoterapi og immunterapi kombineret med probiotika hos patienter med potentiel/resekterbar ikke-småcellet lungekræft
To evaluate the safety and effect of neoadjuvant chemotherapy and immunotherapy combined with probiotics for resectable NSCLC patients.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Hunan
-
Changsha, Hunan, Kina, 410008
- Xiangya Hospital of Central South University
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histologically or cytologically confirmed previously untreated non-small cell lung cancer.
- Patients with resectable stage II, IIIA and IIIB (N2) disease (according to AJCC 8th edition);
- Eastern Cooperative Oncology Group (ECOG) performance status score 0-1;
- 18 years ≤ Age ≤ 80 years;
- Patients with appropriate treatment compliance and could be followed-up correctly;
- Patients with measurable or evaluable diseases (according to RECIST 1.1);
- Patients must have the ability to swallow oral drugs;
- Patients with adequate pulmonary function capable of tolerating the proposed lung resection according to the evidence-based clinical practice guidelines of American College of Chest Physicians;
- Signed and dated written informed consent must be provided by the patient prior to admission to the study.
Exclusion Criteria:
- Subjects with known ALK translocations or EGFR mutations.
- Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll;
- Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease;
- Patients with symptomatic ILD (grade 3-4) and/or poor lung function and a history of interstitial lung disease cannot be included;
- Patients with other active malignant tumors currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or investigational anti-cancer drug;
- Patients who are unable to follow the procedures required in the protocol due to any medical, mental or psychological conditions;
- Prior treatment with an anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody or any other antibodies or drugs that target T cell costimulation or immune checkpoint pathways;
- Known positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid indicating acute or chronic infection;
- Known history of testing positive for human immunodeficiency virus or known acquired immunodeficiency syndrome;
- Patients with a history of allergy to study drugs or ingredients.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Arm 1
3 cycles of nivolumab+Paclitaxel (albumin-bound type)+ Carboplatin AUC5 (21 days/cycle); as well as BiFico (oral taking, 4 capsules/time, 2 times per day) |
3 cycles of nivolumab+Paclitaxel (albumin-bound type)+ Carboplatin AUC5 (21 days/cycle); as well as BiFico (oral taking, 4 capsules/time, 2 times per day)
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pathological complete response
Tidsramme: After surgery, based on surgical resection specimens and blinded independent pathological review.
|
The percentage of participants with 0% residual viable tumor cells in the primary tumor and sampled lymph nodes after neoadjuvant therapy. |
After surgery, based on surgical resection specimens and blinded independent pathological review.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective response rate
Tidsramme: 21 days (±7 days) after the completion of three cycles of neoadjuvant therapy and before surgery.
|
The percentage of participants who achieved complete response or partial response after 3 cycles of neoadjuvant therapy according to the RECIST 1.1 criteria. |
21 days (±7 days) after the completion of three cycles of neoadjuvant therapy and before surgery.
|
|
Clinical TNM downstaging
Tidsramme: 21 days (±7 days) after the completion of three cycles of neoadjuvant therapy and before surgery.
|
Participants who achieve a a reduction in the corresponding radiological T, N, or overall TNM stage compared with baseline. |
21 days (±7 days) after the completion of three cycles of neoadjuvant therapy and before surgery.
|
|
Treatment-related Adverse Events
Tidsramme: Treatment-related adverse events were assessed between the start of the first neoadjuvant dose and 30 days after the last dose of neoadjuvant study treatment.
|
The number of participants with treatment-related adverse events as assessed by CTCAE v5.0. |
Treatment-related adverse events were assessed between the start of the first neoadjuvant dose and 30 days after the last dose of neoadjuvant study treatment.
|
|
Disease free survival
Tidsramme: 1 year, 3 years and 5 years after the operation
|
The time (month) from the completion of lung cancer radical surgery to the recurrence or metastasis of the disease. |
1 year, 3 years and 5 years after the operation
|
|
Recurrence rate
Tidsramme: 1 year, 3 years and 5 years after the operation
|
The percentage of participants who have recurrence or metastasis of lung cancer at certain time points after radical surgery. |
1 year, 3 years and 5 years after the operation
|
|
Overall survival
Tidsramme: 1 year, 3 years and 5 years after the operation
|
The time (month) from the completion of lung cancer radical surgery to all-cause death. |
1 year, 3 years and 5 years after the operation
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studieleder: Yang Gao, Doctor, Xiangya Hospital of Central South University
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Luftvejssygdomme
- Lungesygdomme
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Lungeneoplasmer
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Karcinom, ikke-småcellet lunge
- Organiske kemikalier
- Kulbrinter
- Cycloparaffiner
- Kulbrinter, alicyklisk
- Kulbrinter, cyklisk
- Terpenes
- Kosttilskud
- Mad
- Diæt, mad og ernæring
- Fysiologiske fænomener
- Mad og drikkevarer
- Taxoider
- Cyclodecanes
- Diterpenes
- Genomkomponenter
- Genom
- Genetiske strukturer
- Genetiske fænomener
- Molekylær struktur
- Biokemiske fænomener
- Kemiske fænomener
- Retroelementer
- Ispedte gentagne sekvenser
- Gentagne sekvenser, nukleinsyre
- Basissekvens
- Paclitaxel
- Probiotika
- Short Interspersed Nucleotide Elements
Andre undersøgelses-id-numre
- 202007093
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
all IPD that underlie results in a publication
IPD-delingstidsramme
IPD will be shared when the clinical trail is finished
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .